Skip to main content
. Author manuscript; available in PMC: 2023 Oct 21.
Published in final edited form as: ACS Chem Biol. 2022 Sep 29;17(10):2911–2922. doi: 10.1021/acschembio.2c00565

Figure 4:

Figure 4:

Characterization of macrocyclic peptides for inhibition of interactions between the Spike RBD and ACE2. A) Assays used to characterize inhibition consisted of an AlphaScreen assay to measure protein-protein interactions along with a cytopathogenic effect (CPE) assay that quantified infectivity of SARS-CoV-2 in Vero E6 cells. B) Inhibition of Spike RBD:ACE2 interactions by P29S1 using the AlphaScreen assay. Data points are presented as mean ± SEM of four biologically independent replicates (N=3). C) Live virus inhibition using P29S1 (red) and P28S1 (blue). Data points are presented as mean ± SD of three biologically independent experiments (N = 3). D) Summary of inhibition data for each of the tested peptides. NI = No inhibition. ND = Not determined. All data is reported as mean ± SD for three independent experiments (N = 3).